International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019.
Adult
Aged
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Female
Health Priorities
/ organization & administration
Health Services Accessibility
/ standards
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Pandemics
/ prevention & control
Pneumonia, Viral
/ prevention & control
Randomized Controlled Trials as Topic
/ standards
Research Design
SARS-CoV-2
Symptom Assessment
COVID-19 Drug Treatment
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
18
8
2020
medline:
23
10
2020
entrez:
18
8
2020
Statut:
ppublish
Résumé
There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. In an online survey conducted in English, Chinese, Italian, Portuguese, and Spanish languages, adults with coronavirus disease 2019, their family members, health professionals, and the general public rated the importance of outcomes using a 9-point Likert scale (7-9, critical importance) and completed a Best-Worst Scale to estimate relative importance. Participant comments were analyzed thematically. International. Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public, and health professionals (including clinicians, policy makers, regulators, funders, and researchers). None. None. In total, 9,289 participants from 111 countries (776 people with coronavirus disease 2019 or family members, 4,882 health professionals, and 3,631 members of the public) completed the survey. The four outcomes of highest priority for all three groups were: mortality, respiratory failure, pneumonia, and organ failure. Lung function, lung scarring, sepsis, shortness of breath, and oxygen level in the blood were common to the top 10 outcomes across all three groups (mean > 7.5, median ≥ 8, and > 70% of respondents rated the outcome as critically important). Patients/family members rated fatigue, anxiety, chest pain, muscle pain, gastrointestinal problems, and cardiovascular disease higher than health professionals. Four themes underpinned prioritization: fear of life-threatening, debilitating, and permanent consequences; addressing knowledge gaps; enabling preparedness and planning; and tolerable or infrequent outcomes. Life-threatening respiratory and other organ outcomes were consistently highly prioritized by all stakeholder groups. Patients/family members gave higher priority to many patient-reported outcomes compared with health professionals.
Identifiants
pubmed: 32804789
doi: 10.1097/CCM.0000000000004584
pmc: PMC7448718
pii: 00003246-202011000-00009
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1612-1621Subventions
Organisme : Wellcome Trust
ID : 205214/Z/16/Z
Pays : United Kingdom
Références
JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Med Virol. 2020 Jul;92(7):776-785
pubmed: 32297988
Br J Psychiatry. 2020 Jul;217(1):351
pubmed: 32270760
Engineering (Beijing). 2020 Oct;6(10):1147-1152
pubmed: 32292626
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Asian J Psychiatr. 2020 Jun;51:102106
pubmed: 32334411
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Front Pharmacol. 2020 May 25;11:781
pubmed: 32574235
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Crit Care Med. 2020 Sep;48(9):e799-e804
pubmed: 32452888
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
J Health Econ. 2007 Jan;26(1):171-89
pubmed: 16707175
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
J Crit Care. 2020 Oct;59:176-190
pubmed: 32683212